Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.

Jakob M Riedl; Florian Posch; Lena Horvath; Antonia Gantschnigg; Felix Renneberg; Esther Schwarzenbacher; Florian Moik; Dominik A Barth; Christopher H Rossmann; Michael Stotz; Renate Schaberl-Moser; Martin Pichler; Herbert Stöger; Richard Greil; Angela Djanani; Konstantin Schlick; Armin Gerger

doi:10.1016/j.ejca.2021.03.040

Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.

Jakob M Riedl
, Florian Posch
, Lena Horvath
, Antonia Gantschnigg (Co-author)
, Felix Renneberg (Co-author)
, Esther Schwarzenbacher
, Florian Moik
, Dominik A Barth
, Christopher H Rossmann
, Michael Stotz
, Renate Schaberl-Moser
, Martin Pichler
, Herbert Stöger
, Richard Greil (Co-author)
, Angela Djanani
, Konstantin Schlick (Co-author)
, Armin Gerger

Department of Surgery
Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

48 Citations (Web of Science)

Original language	English
Pages (from-to)	3-13
Journal	EUROPEAN JOURNAL OF CANCER
Volume	151
DOIs	https://doi.org/10.1016/j.ejca.2021.03.040
Publication status	Published - 2021

Keywords

NAB-PACLITAXEL
CHEMOTHERAPY
SURVIVAL
THERAPY
BENEFIT

Access to Document

10.1016/j.ejca.2021.03.040

Cite this

Riedl, J. M., Posch, F., Horvath, L., Gantschnigg, A., Renneberg, F., Schwarzenbacher, E., Moik, F., Barth, D. A., Rossmann, C. H., Stotz, M., Schaberl-Moser, R., Pichler, M., Stöger, H., Greil, R., Djanani, A., Schlick, K., & Gerger, A. (2021). Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. EUROPEAN JOURNAL OF CANCER , 151, 3-13. https://doi.org/10.1016/j.ejca.2021.03.040

Riedl, Jakob M ; Posch, Florian ; Horvath, Lena et al. / Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. In: EUROPEAN JOURNAL OF CANCER 2021 ; Vol. 151. pp. 3-13.

@article{842f548570304153be0c76e729341a8c,

title = "Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.",

keywords = "NAB-PACLITAXEL, CHEMOTHERAPY, SURVIVAL, THERAPY, BENEFIT",

author = "Riedl, \{Jakob M\} and Florian Posch and Lena Horvath and Antonia Gantschnigg and Felix Renneberg and Esther Schwarzenbacher and Florian Moik and Barth, \{Dominik A\} and Rossmann, \{Christopher H\} and Michael Stotz and Renate Schaberl-Moser and Martin Pichler and Herbert St{\"o}ger and Richard Greil and Angela Djanani and Konstantin Schlick and Armin Gerger",

note = "Gantschnigg: Paracelsus Med Univ, Dept Surg, Salzburg, Austria; Renneberg; Greil; Schlick: Paracelsus Med Univ, Salzburg Canc Res Inst, Med Dept Hematol Med Oncol Hemostaseol Rheumatol, Salzburg, Austria;",

year = "2021",

doi = "10.1016/j.ejca.2021.03.040",

language = "English",

volume = "151",

pages = "3--13",

journal = "EUROPEAN JOURNAL OF CANCER ",

issn = "0959-8049",

publisher = "Elsevier ",

}

Riedl, JM, Posch, F, Horvath, L, Gantschnigg, A , Renneberg, F, Schwarzenbacher, E, Moik, F, Barth, DA, Rossmann, CH, Stotz, M, Schaberl-Moser, R, Pichler, M, Stöger, H, Greil, R, Djanani, A, Schlick, K & Gerger, A 2021, 'Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.', EUROPEAN JOURNAL OF CANCER , vol. 151, pp. 3-13. https://doi.org/10.1016/j.ejca.2021.03.040

Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. / Riedl, Jakob M; Posch, Florian; Horvath, Lena et al.
In: EUROPEAN JOURNAL OF CANCER , Vol. 151, 2021, p. 3-13.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.

AU - Riedl, Jakob M

AU - Posch, Florian

AU - Horvath, Lena

AU - Gantschnigg, Antonia

AU - Renneberg, Felix

AU - Schwarzenbacher, Esther

AU - Moik, Florian

AU - Barth, Dominik A

AU - Rossmann, Christopher H

AU - Stotz, Michael

AU - Schaberl-Moser, Renate

AU - Pichler, Martin

AU - Stöger, Herbert

AU - Greil, Richard

AU - Djanani, Angela

AU - Schlick, Konstantin

AU - Gerger, Armin

N1 - Gantschnigg: Paracelsus Med Univ, Dept Surg, Salzburg, Austria; Renneberg; Greil; Schlick: Paracelsus Med Univ, Salzburg Canc Res Inst, Med Dept Hematol Med Oncol Hemostaseol Rheumatol, Salzburg, Austria;

PY - 2021

Y1 - 2021

KW - NAB-PACLITAXEL

KW - CHEMOTHERAPY

KW - SURVIVAL

KW - THERAPY

KW - BENEFIT

U2 - 10.1016/j.ejca.2021.03.040

DO - 10.1016/j.ejca.2021.03.040

M3 - Original Article

C2 - 33951545

SN - 0959-8049

VL - 151

SP - 3

EP - 13

JO - EUROPEAN JOURNAL OF CANCER

JF - EUROPEAN JOURNAL OF CANCER

ER -

Riedl JM, Posch F, Horvath L, Gantschnigg A , Renneberg F, Schwarzenbacher E et al. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. EUROPEAN JOURNAL OF CANCER . 2021;151:3-13. doi: 10.1016/j.ejca.2021.03.040